Stempoint Capital’s Quince Therapeutics QNCX Stock Holding History

Stempoint Capital’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,696	Closed	-$2.48M	–	110
2025 Q4	$2.48M	Buy	+3,696	New	+$1.86M	0.42%	53

Other funds holding QNCX

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Stempoint Capital's QNCX Position: Q1 2026 in Review

Stempoint Capital sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 3,696 shares — an estimated $2.48M sold.

Stempoint Capital first reported a position in QNCX in Q4 2025 and held it in 1 quarter. The position peaked at $2.48M in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

Stempoint Capital reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 3,696 Quince Therapeutics shares in Q1 2026, an estimated $2.48M.
Stempoint Capital first reported a position in Quince Therapeutics in Q4 2025 and held it in 1 quarter.
Stempoint Capital's Quince Therapeutics position peaked at $2.48M in Q4 2025.
43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.